Published in Ann Surg Oncol on July 28, 2009
Favorable outcomes with laparoscopic surgery for rectal cancer. Surg Endosc (2010) 1.42
Sentinel node biopsy in laparoscopic surgical oncology. Surg Endosc (2011) 1.38
Prophylactic laparoscopic gastrectomy for hereditary diffuse gastric cancer: a case series in a single family. JSLS (2011) 0.88
Laparoscopic total gastrectomy: further progress in gastric cancer. Surg Endosc (2010) 0.86
Mediastinal lymphadenopathy: assessing clinical utility of EUS-FNA. Surg Endosc (2011) 0.83
Proximal gastric cancer: advances of laparoscopic surgery. Surg Endosc (2011) 0.82
Synchronous appendiceal and intramucosal gastric signet ring cell carcinomas in an individual with CDH1-associated hereditary diffuse gastric carcinoma: a case report of a novel association and review of the literature. BMC Gastroenterol (2013) 0.80
Right colectomy: is it a safe and feasible totally laparoscopic approach with transvaginal specimen extraction. Surg Endosc (2011) 0.79
[Hereditary gastric cancer]. Pathologe (2010) 0.78
Open versus laparoscopic versus robotic gastrectomy for cancer: need for comparative-effectiveness quality. Surg Endosc (2010) 0.78
Laparoscopic sphincter-preserving rectal cancer surgery: a highly demanding procedure. Surg Endosc (2010) 0.78
Prophylactic Laparoscopic Total Gastrectomy with Jejunal Pouch Reconstruction in Patients Carrying a CDH1 Germline Mutation. J Gastrointest Surg (2015) 0.77
Robotic versus laparoscopic surgery for rectal cancer and cost-effectiveness analysis. Surg Endosc (2011) 0.77
Outweighing the benefits and weakness of endoscopic submucosal dissection for early gastric cancer in the west. Surg Endosc (2010) 0.76
Single-incision laparoscopic surgery for colorectal cancer. Surg Endosc (2011) 0.75
Reducing anastomotic leakage in laparoscopic low anterior resection: is it achievable by a new method? Surg Endosc (2011) 0.75
Endoscopic submucosal dissection for remnant gastric cancer. Surg Endosc (2010) 0.75
Metachronous cancer in the stomach remnant. World J Surg (2011) 0.75
Optimizing locoregional staging in the preoperative setting of resectable esophageal cancer. Surg Endosc (2011) 0.75
Laparoscopic and robotic-assisted D2 surgery for gastric cancer: a reality in Europe? Surg Endosc (2011) 0.75
Extraperitoneal rectal cancer: why laparoscopic may be more effective than open surgery. Surg Endosc (2011) 0.75
Remnant gastric cancer: can the risk be predicted when planning initial surgery? World J Surg (2011) 0.75
Comparative-effectiveness research and good clinical practice for laparoscopic rectal surgery after neoadjuvant treatment. Surg Endosc (2011) 0.75
Exploring indications for laparoscopic primary tumor resection in metastatic colorectal cancer. Surg Endosc (2011) 0.75
Moving from lymph nodes measurement to standardizing colon cancer surgery: letter to the editor. World J Surg (2010) 0.75
From evidence to a day-to-day laparoscopic colectomy. Surg Endosc (2011) 0.75
Robotic surgery and limitations. Surg Endosc (2012) 0.75
Predictive factors for improving survival after gastrectomy in gastric cancer patients with peritoneal carcinomatosis. World J Surg (2010) 0.75
Totally laparoscopic total gastrectomy and the challenge of esophagojejunostomy. Surg Endosc (2011) 0.75
Pancreatic cancer: the challenge of the future in tumorigenesis-based prevention. World J Surg (2011) 0.75
Nonepithelial, submucosal gastric tumors: is laparoscopic wedge resection the optimal treatment? Surg Endosc (2011) 0.75
Assessing superiority: intracorporeal versus extracorporeal anastomosis for laparoscopic colon resection. Surg Endosc (2011) 0.75
Monitoring and assessing the intraabdominal therapeutic response for gastric cancer: is second-look laparoscopy the solution? Surg Endosc (2010) 0.75
Advances and high demands in totally robotic surgery for rectal cancer. Surg Endosc (2011) 0.75
Prognostic significance of host- and tumor-related factors in patients with gastric cancer. World J Surg (2010) 0.75
Linking epidermal growth factor plasma levels with the prognosis and treatment response of colorectal cancer patients treated with a minimally invasive approach: does it have clinical utility? Surg Endosc (2011) 0.75
Surgeon's volume and number of lymph nodes in assessing colorectal cancer surgery and multimodal treatment quality. Surg Endosc (2010) 0.75
Laparoscopic restorative proctocolectomy with ileal pouch-anal anastomosis for ulcerative colitis and impact of anti-tumor necrosis factor on postoperative outcomes. Surg Endosc (2011) 0.75
Thoracolaparoscopic esophagectomy: further improvement in the multimodal treatment of esophageal cancer. Surg Endosc (2011) 0.75
Optimizing lymphadenectomy in laparoscopic surgery for colon cancer. Surg Endosc (2010) 0.75
Adjuvant S-1 chemotherapy for gastric cancer and peritoneal wash. World J Surg (2011) 0.75
Laparoscopic surgery for rectal cancer: the standard of care? Surg Endosc (2010) 0.75
Simultaneous resection of primary colorectal cancer and synchronous liver metastases. World J Surg (2011) 0.75
Laparoscopic low vs. high anterior resection for rectal cancer. Surg Endosc (2010) 0.75
Genotyping gastric cancer. World J Surg (2011) 0.75
Minimally invasive esophagectomy. Surg Endosc (2010) 0.75
Challenges with identification of angiogenesis biomarkers in cancer. Surg Endosc (2011) 0.75
To resect or not the primary tumor in metastatic colorectal cancer. World J Surg (2010) 0.75
Cost-effectiveness analyses of laparoscopic versus open surgery. Surg Endosc (2011) 0.75
Challenges in the treatment of gastroesophageal junction cancer. World J Surg (2011) 0.75
Recovery after laparoscopic right hemicolectomy for colon cancer. Surg Endosc (2011) 0.75
Predicting and preventing anastomotic leakage after low anterior resection for rectal cancer. World J Surg (2011) 0.75
Laparoscopic colorectal cancer resection: examining lymph nodes or standardizing surgery? Surg Endosc (2010) 0.75
Curability risks by endoscopic submucosal dissection for early gastric cancer. Surg Endosc (2010) 0.75
Endoscopic and laparoscopic ultrasonography used to predict tumor staging and improve therapeutic decisions for upper gastrointestinal tract cancer. Surg Endosc (2012) 0.75
Sparing minilaparotomy in robotic low anterior resection for cancer. Surg Endosc (2010) 0.75
The identification and management of hereditary diffuse gastric cancer in a large Jordanian family. Fam Cancer (2011) 0.75
High-quality clinical practice: laparoscopic rectal cancer resection. Surg Endosc (2010) 0.75
E-cadherin germline mutations in familial gastric cancer. Nature (1998) 6.72
Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. JAMA (2007) 3.62
Genetic variation in PSCA is associated with susceptibility to diffuse-type gastric cancer. Nat Genet (2008) 2.89
Hereditary diffuse gastric cancer: diagnosis, genetic counseling, and prophylactic total gastrectomy. Cancer (2008) 1.06
Mea Culpa with cancer-targeted therapy: new thinking and new agents design for novel, causal networks-based, personalized biomedicine. Expert Rev Mol Diagn (2009) 1.05
Personalized cancer diagnostics and therapeutics. Expert Rev Mol Diagn (2009) 1.04
Genome-wide association studies and aggressive surgery toward individualized prevention, and improved local control and overall survival for gastric cancer. Ann Surg Oncol (2009) 0.99
Prophylactic total gastrectomy (PTG) for hereditary diffuse gastric cancer (HDGC): the Newfoundland experience with 23 patients. Ann Surg Oncol (2009) 0.99
Genome-wide association studies: how predictable is a person's cancer risk? Expert Rev Anticancer Ther (2009) 0.98
Assessing both genetic variation (SNPs/CNVs) and gene-environment interactions may lead to personalized gastric cancer prevention. Expert Rev Mol Diagn (2009) 0.97
Level I evidence in support of perioperative chemotherapy for operable gastric cancer: sufficient for wide clinical use? Ann Surg Oncol (2007) 2.27
Is it time to change surgical strategy for gastric cancer in the United States? Ann Surg Oncol (2004) 1.48
New technology-based innovation changes surgical practice and research direction in solid cancers. Surg Endosc (2010) 1.39
The role of HPV DNA testing in the follow-up period after treatment for CIN: a systematic review of the literature. Cancer Treat Rev (2004) 1.18
From next-generation sequencing to nanopore sequencing technology: paving the way to personalized genomic medicine. Expert Rev Med Devices (2013) 1.16
Targeting gastric cancer with trastuzumab: new clinical practice and innovative developments to overcome resistance. Ann Surg Oncol (2009) 1.14
Mea Culpa with cancer-targeted therapy: new thinking and new agents design for novel, causal networks-based, personalized biomedicine. Expert Rev Mol Diagn (2009) 1.05
Personalized cancer diagnostics and therapeutics. Expert Rev Mol Diagn (2009) 1.04
Gene discovery in familial cancer syndromes by exome sequencing: prospects for the elucidation of familial colorectal cancer type X. Mod Pathol (2012) 1.01
Prognosis of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med (2007) 1.01
Randomized evidence for laparoscopic gastrectomy short-term quality of life improvement and challenges for improving long-term outcomes. Ann Surg (2009) 0.99
Robotic surgery for rectal cancer: may it improve also survival? Surg Endosc (2008) 0.99
Genome-wide association studies and aggressive surgery toward individualized prevention, and improved local control and overall survival for gastric cancer. Ann Surg Oncol (2009) 0.99
Selecting a specific pre- or postoperative adjuvant therapy for individual patients with operable gastric cancer. Expert Rev Anticancer Ther (2006) 0.99
Complete genome sequencing and network modeling to overcome trastuzumab resistance. Pharmacogenomics (2010) 0.99
Impact of spleen preservation in patients with gastric cancer. Anticancer Res (2005) 0.99
Next-generation, genome sequencing-based biomarkers: concerns and challenges for medical practice. Biomark Med (2010) 0.99
Genome-wide association studies: how predictable is a person's cancer risk? Expert Rev Anticancer Ther (2009) 0.98
Assessing both genetic variation (SNPs/CNVs) and gene-environment interactions may lead to personalized gastric cancer prevention. Expert Rev Mol Diagn (2009) 0.97
Personal genomics and genome-wide association studies: novel discoveries but limitations for practical personalized medicine. Ann Surg Oncol (2008) 0.96
Breast cancer outcomes: the crucial role of the breast surgeon in the era of personal genetics and systems biology. Ann Surg (2009) 0.95
Factors increasing local recurrence in breast-conserving surgery. Expert Rev Anticancer Ther (2005) 0.95
Laparoscopic gastrectomy and personal genomics: high-volume surgeons and predictive biomedicine may govern the future for resectable gastric cancer. Ann Surg (2009) 0.94
Laparoscopic colectomy survival benefit for colon cancer: is evidence from a randomized trial true? Ann Surg (2009) 0.93
Next-generation sequencing and epigenome technologies: potential medical applications. Expert Rev Med Devices (2010) 0.93
Bionetworks-based personalized medicine versus comparative-effectiveness research or harmonization of both in cancer management? Expert Rev Mol Diagn (2010) 0.92
Twenty-one-gene assay: challenges and promises in translating personal genomics and whole-genome scans into personalized treatment of breast cancer. J Clin Oncol (2009) 0.92
Identifying and preventing high-risk gastric cancer individuals with CDH1 mutations. Ann Surg (2008) 0.92
The predominant role of surgery in the prevention and new trends in the surgical treatment of women with BRCA1/2 mutations. Ann Surg Oncol (2007) 0.91
Genetics and personal genomics for personalized breast cancer surgery: progress and challenges in research and clinical practice. Ann Surg Oncol (2009) 0.90
Genotype-phenotype map and molecular networks: a promising solution in overcoming colorectal cancer resistance to targeted treatment. Expert Rev Mol Diagn (2010) 0.90
Radiation therapy for breast cancer. N Engl J Med (2009) 0.89
Cancer genome explosion and systems biology: impact on surgical oncology? Ann Surg Oncol (2011) 0.89
Laparoscopic surgery for gastric cancer: comparative-effectiveness research and future trends. Expert Rev Anticancer Ther (2010) 0.89
Systems medicine: a real approach for future personalized oncology? Pharmacogenomics (2010) 0.89
Targeting the optimal extent of lymph node dissection for gastric cancer. J Surg Oncol (2002) 0.88
Radiation burden of patients undergoing endovascular abdominal aortic aneurysm repair. J Vasc Surg (2009) 0.88
Translating epigenetics into an anticancer drug pipeline for solid tumors. Expert Rev Med Devices (2011) 0.88
Networks medicine: from reductionism to evidence of complex dynamic biomolecular interactions. Pharmacogenomics (2011) 0.88
Is there any long-term benefit in quality of life after laparoscopy-assisted distal gastrectomy for gastric cancer? Surg Endosc (2008) 0.87
Measurable evidence of miRNAs as regulators of cancer networks and therapeutic targets. Expert Rev Med Devices (2011) 0.87
From tumor size and HER2 status to systems oncology for very early breast cancer treatment. Expert Rev Anticancer Ther (2010) 0.87
Current concerns and challenges regarding tailored anti-angiogenic therapy in cancer. Expert Rev Anticancer Ther (2009) 0.86
Laparoscopic total gastrectomy: further progress in gastric cancer. Surg Endosc (2010) 0.86
Beyond HER2 and trastuzumab: heterogeneity, systems biology, and cancer origin research may guide the future for personalized treatment of very early but aggressive breast cancer. J Clin Oncol (2010) 0.86
Linking contralateral breast cancer with genetics. Radiother Oncol (2008) 0.85
Isolated tumor cells in breast cancer. N Engl J Med (2009) 0.85
HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med (2008) 0.84
Breast-cancer stromal cells with TP53 mutations. N Engl J Med (2008) 0.84
Quality of surgery determinant for the outcome of patient with gastric cancer. Ann Surg Oncol (2002) 0.84
Human genetic and structural genomic variation: would genome-wide association studies be the solution for cancer complexity like Alexander the Great for the "Gordian Knot"? Ann Surg Oncol (2008) 0.83
Approaching the dilemma between prophylactic bilateral mastectomy or oophorectomy for breast and ovarian cancer prevention in carriers of BRCA1 or BRCA2 mutations. Ann Surg Oncol (2002) 0.83
'Big' science: genome regulatory networks and novel molecular tools to improve health. Expert Rev Mol Diagn (2011) 0.83
Genome diagnostics: next-generation sequencing, new genome-wide association studies and clinical challenges. Expert Rev Mol Diagn (2011) 0.83
Highly elevated serum levels of CA 19-9 in choledocholithiasis: a case report. Cases J (2009) 0.83
Caution in adding bevacizumab in the adjuvant treatment of breast cancer. Ann Surg Oncol (2009) 0.83
Role of surgery in the prophylaxis of hereditary cancer syndromes. Ann Surg Oncol (2002) 0.83
Circulating tumor DNA: new horizons for improving cancer treatment. Future Oncol (2015) 0.83
Adjuvant chemoradiotherapy in gastric cancer: wave goodbye to extensive surgery? Ann Surg Oncol (2002) 0.82
Genomics and challenges toward personalized breast cancer local control. J Clin Oncol (2008) 0.82
Clinical relevance of cancer genome sequencing. World J Gastroenterol (2013) 0.82
Pathology findings and validation of gastric and esophageal cancer cases in a European cohort (EPIC/EUR-GAST). Scand J Gastroenterol (2007) 0.82
More controversy than ever - challenges and promises towards personalized treatment of gastric cancer. Ann Surg Oncol (2008) 0.81
Differential signaling transduction networks for clinical robustness. Expert Rev Proteomics (2012) 0.81
Laparoscopic gastrectomy for organ-confined cancer: a reality in the West? Surg Endosc (2009) 0.81
Neoadjuvant chemotherapy for breast cancer: does pretreatment axillary nodal staging improve decision making? Ann Surg Oncol (2009) 0.81
New target therapies for patients with neuroendocrine tumors of the pancreas. Expert Rev Gastroenterol Hepatol (2011) 0.81
Spatiotemporal individual genome code-lifestyle network: revolutionizing personal diagnostics. Expert Rev Mol Diagn (2012) 0.81
Clinical cancer genome and precision medicine. Ann Surg Oncol (2012) 0.80
Early-stage gastric cancer: a highly treatable disease. Ann Surg Oncol (2004) 0.80
Biotechnological, genomics and systems-synthetic biology revolution: redesigning genetic code for a pragmatic systems medicine. Expert Rev Med Devices (2012) 0.80
Perspectives and risks of breast-conservation therapy for breast cancer. Ann Surg Oncol (2003) 0.79
Emerging personalized oncology: sequencing and systems strategies. Future Oncol (2012) 0.79
Innovation versus evidence: to trust direct-to-consumer personal genomic tests? Expert Rev Mol Diagn (2011) 0.79
Colorectal liver metastases guidelines, tumor heterogeneity and clonal evolution: can this be translated to patient benefit? Future Oncol (2014) 0.79
PLX4032 and melanoma: resistance, expectations and uncertainty. Expert Rev Anticancer Ther (2011) 0.79
Contralateral prophylactic mastectomy: mind the genetics. J Clin Oncol (2008) 0.79
Progress, challenges and new genome-based concepts in the multidisciplinary treatment of gastric cancer. Expert Rev Anticancer Ther (2011) 0.78
Laparoscopic and robotic rectal cancer resection: expectations for improving oncological outcomes. Ann Surg (2010) 0.78
Totally intracorporeal laparoscopic gastrectomy for gastric cancer. Surg Endosc (2010) 0.78
Controversy in the treatment of gastric cancer. Ann Surg Oncol (2008) 0.78
HER2 and trastuzumab: impact of a new standard agent on local control and surgery for breast cancer. Ann Surg Oncol (2008) 0.78
Disrupting cancer cells' biocircuits with interactome-based drugs: is 'clinical' innovation realistic? Expert Rev Proteomics (2012) 0.77
Research and clinical applications of cancer genome sequencing. Curr Opin Obstet Gynecol (2013) 0.77
Colorectal cancer: cetuximab, KRAS, BRAF, PIK3CA mutations and beyond. Expert Rev Gastroenterol Hepatol (2010) 0.77
EGFR as a Prognostic Marker for Gastric Cancer. World J Surg (2008) 0.77
Cancer heterogeneity and signaling network-based drug target. Pharmacogenomics (2013) 0.77
Targeting VEGF, EGFR, and other interacting pathways for gastric cancer-promises and reality. Ann Surg Oncol (2008) 0.77
Translating cancer genomes sequencing revolution into surgical oncology practice. J Surg Res (2010) 0.77
Fruits and vegetables: do they protect from gastric cancer? Gastroenterology (2003) 0.77
Gastroesophageal junction carcinoma multimodal treatment: standards, debate and new therapeutic options. Expert Rev Gastroenterol Hepatol (2011) 0.77
BMI and lymph node ratio may predict clinical outcomes of gastric cancer. Future Oncol (2014) 0.77
Innovative biomarker development for personalized medicine in breast cancer care. Biomark Med (2011) 0.77
Pharmacogenomics for tailoring cardiovascular and anticancer drugs: from genotyping to whole-genome sequencing. Pharmacogenomics (2011) 0.77
Longevity with systems medicine? Epigenome, genome and environment interactions network. Epigenomics (2012) 0.77
Trastuzumab emtansine for advanced HER2-positive breast cancer and beyond: genome landscape-based targets. Expert Rev Anticancer Ther (2013) 0.76
Mapping inherited and somatic variation in regulatory DNA: new roadmap for common disease clinical discoveries. Expert Rev Mol Diagn (2013) 0.76